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Interest in bacteriophages as therapeutic agents has recently been reawakened. Parenteral delivery is the
most routinely-employed method of administration. However, injection of phages has numerous disad-
vantages, such as the requirement of a health professional for administration and the possibility of cross-
contamination. Transdermal delivery offers one potential means of overcoming many of these problems.
The present study utilized a novel poly (carbonate) (PC) hollow microneedle (MN) device for the trans-
dermal delivery of Escherichia coli-speciﬁc T4 bacteriophages both in vitro and in vivo. MN successfully
achieved bacteriophage delivery in vitro across dermatomed and full thickness skin. A concentration of
2.67  106 PFU/ml (plaque forming units per ml) was detected in the receiver compartment when deliv-
ered across dermatomed skin and 4.0  103 PFU/ml was detected in the receiver compartment when
delivered across full thickness skin. An in vivo study resulted in 4.13  103 PFU/ml being detected in
blood 30 min following initial MN-mediated phage administration. Clearance occurred rapidly, with
phages being completely cleared from the systemic circulation within 24 h, which was expected in the
absence of infection. We have shown here that MN-mediated delivery allows successful systemic phage
absorption. Accordingly, bacteriophage-based therapeutics may now have an alternative route for sys-
temic delivery. Once fully-investigated, this could lead to more widespread investigation of these inter-
esting therapeutic viruses.
 2012 Elsevier B.V. Open access under CC BY license.1. Introduction The possibility of utilising bacteriophage therapy to treatBacteriophages (20–200 nm in size) are bacterial viruses which
speciﬁcally infect bacteria. In the case of lytic phages, they disrupt
normal bacterial metabolism in favour of viral replication and
cause the bacterium to rapidly lyse (Hendrix, 2002). Despite pre-
dating the discovery of antibiotics by several decades, bacterio-
phage therapy was largely supplanted by antibiotics and vaccines
and their use in western medicine declined. However, the emer-
gence of multidrug-resistant pathogenic bacteria, combined with
a concomitant increase in numbers of immunosuppressed patients,
raises concerns common to the ‘pre-antibiotic era’, which was
characterised by untreatable infectious diseases. Whilst some
new antibiotics have been developed, overall industry effort into
antibacterial drug development has declined, with several major
Pharma companies exiting the ﬁeld or aggressively downsizing
their development programmes (Payne and Tomasz, 2004). There-
fore, development of alternative antimicrobial modalities is ur-
gently required and has become a major priority in modern
biotechnology (Sulakvelidze et al., 2001).; fax: +44 (0) 28 90 247 794.
ly).
Y license.infectious diseases has received increasing attention in recent
years, as several advantages over conventional therapeutic agents
have been recognised. Bacteriophage are (i) highly speciﬁc, thus
unlikely to disturb normal ﬂora in the same manner as conven-
tional chemotherapeutic agents and have the potential to be self-
replicating, facilitating effective treatment by delivery of a low
phage dose, and self-limiting therapeutic agents; (ii) safe, under-
scored by their extensive use in the former Soviet Union and East-
ern Europe and their widespread sale in the US by companies such
as Eli Lilly and E.R. Squibb & Sons in the 1930–1940s and (iii) are
rapidly modiﬁable to combat emergence of bacterial resistance. In-
deed, resistance may be easily circumvented by delivering a ‘phage
cocktail’ directed against numerous strains of the target species.
Signiﬁcantly, phages are also capable of treating intra-cellular
antibiotic-resistant pathogens, such as Mycobacterium avium and
Mycobacterium tuberculosis (Broxmeyer et al., 2002).
Phage biology may be manipulated, primarily via phage display
techniques, for a plethora of other applications in nanomedicine.
Delivery of suitably-engineered phage has permitted isolation of
allergens inducing IgE production using high throughput screening
technologies (Rhyner et al., 2004). Gene delivery to mammalian
cells has also been achieved by the use of single and double
stranded phage by a number of groups (Yokohama-Kobayashi
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particular application may well have signiﬁcant advantages over
standard gene delivery vectors in terms of increased selectivity
(and thus, efﬁcacy) and reduced toxicity (Arap, 2005). Further-
more, tumour targeting peptides identiﬁed by phage display have
been utilised for selective delivery of cytotoxic therapeutic agents
to tumours, highlighting the potential for drug and drug delivery
vector discovery by in vivo delivery of bacteriophage libraries (Arap
et al., 1998). Phages can also be engineered to bear target-speciﬁc
peptides or proteins for biorecognition, and thus may have applica-
tion in development of novel chemical and biological sensors that
may provide quantitative or semi-quantitative data through
exploitation of a chemical or biological recognition element (Mao
et al., 2009).
Bacteriophages do have some local activity when given orally,
but only on infectious microorganisms in the gut. Absorption of in-
tact bacteriophages into the systemic circulation does not take
place following oral administration (Bruttin and Brüssow, 2004)
and bile salts and intestinal carbohydrates may sequester the
bivalent metal ions needed for phage replication (Chibani-Chen-
nouﬁ et al., 2004). Inhalation-based delivery of bacteriophages
has proved inefﬁcient in animal studies (Huff et al., 2003). Conse-
quently, parenteral delivery is the most routinely-employed meth-
od for administering bacteriophages. However, parenteral
administration of therapeutics is associated with signiﬁcant prob-
lems, including the need for trained personnel, the risk of blood-
borne pathogen transmission, the frequent need for maintenance
of an expensive ‘cold chain’ and relatively poor compliance (Morris
et al., 1997). Nevertheless, despite the recognised problems with
delivery and administration, there is increasing interest in devel-
opment of phage-based therapeutics/diagnostics.
The success of bacteriophage-derived therapeutics and biosen-
sors will ultimately rely on suitably robust, reproducible, delivery
technologies. In particular, bacteriophage-based treatment of
common infectious diseases will only be practical if these ad-
vanced medicines can be conveniently and routinely self-admin-
istered by patients in their own homes. Transdermal delivery
(Williams, 2003; Barry, 2001) offers one potential means of over-
coming many of the problems associated with systemic delivery
of bacteriophages. Clearly bacteriophages, being viruses rather
than small relatively lipophilic drug molecules, do not satisfy
the criteria for efﬁcient transdermal absoprtion. Nevertheless,
the transdermal delivery of these potent therapeutic agents is of
particular interest, as it may overcome many of the problems
associated with conventional delivery methods. To date, transder-
mal delivery of bacteriophages has not been considered. However,
novel microneedle technologies, developed by our Group and oth-
ers, have now made this a possibility, particularly for thermola-
bile biomolecules and biological entities (Donnelly et al., 2010a,
2010b, 2011; Mikolajewska et al., 2010; Migalska et al., 2011;
Prausnitz, 2004; Garland et al., 2011). In this paper, we report
for the ﬁrst time, design and evaluation of a novel hollow
polymeric microneedle device for transdermal bacteriophage
delivery.2. Materials and methods
2.1. Materials
T4 bacteriophage ATCC B11303 and host strain Escherichia coli
11303 ATCC 11303 were purchased from LGC standards, Middle-
sex, UK. Luria Bertani (LB) agar was purchased from Sigma–Aldrich,
Dorset, UK. Stock phage solutions were stored at 4 C and protected
from light. E. coli was frozen with cryoprotectant beads and glyc-
erol and stored at60 C. Isoﬂurane inhalation anaesthetic was ob-tained from Abbott Laboratories Ltd., Kent, UK. All other chemicals
used were of analytical reagent grade.
2.2. Fabrication of poly(carbonate) (PC) hollow microneedle arrays
Microneedles (MNs) were manufactured using a prototype
micromoulding process. Mould cavities and inserts were micro-
machined from brass and inset pins were machined from H-13 tool
steel using a specialized Electric Discharge Machining (EDM) pro-
cess. The moulds were run on an Arburg 221 KS Allrounder mould-
ing machine. MNs were manufactured from PC. The prototype
array of MNs consisted of seven needles at 3 mm centers on a
21 mm  21 mm base. The MNs were 1 mm in height with a
100 lm off-centre through-hole. The aspect ratio was 1.6:1. The
tip sharpness of the prototype needles was approximately 25 lm
in radius. The MN array was ultrasonically welded to a reservoir
array of the same material as the MN array consisting of a 5 ll
reservoir well for each MN. A silicone sealing gasket was used
in-between the MN array and reservoir array.
2.3. Microscopy techniques
To observe MN morphology, images of the MNs were taken
using a Leica DC150 digital microscope (Leica, Wetzlar, Germany).
MNs were attached to aluminium stubs using double-sided adhe-
sive and coated at 2.5 kV, 18 mA with gold for 45 s (POLARON
E5150, Gold Sputter Coater, Quorum Technologies, East Sussex,
UK). The images were then obtained using a Scanning Electron
Microscope (JOEL JSM 840, Joel Ltd., Tokyo, Japan).
The MN arrays were also visualised using a Phoenix X-ray nano-
tom system (GE, London, UK), under the following conditions; en-
ergy: 55 kV, current: 160 mA, nanotom mode: 0, voxel resolution:
10 lm, number of projections: 720, image averaging: 3, detector
timing: 1500 ms, binning mode: 1  1 (no binning). The method
involved the acquisition of a series of X-ray projection images at
a known number of angular positions through 360. Variation in
the contrast of each projection image relates to how the x-rays
are attenuated as they penetrate the sample. Axial slice views were
computed from the X-ray projections using back projection recon-
struction algorithms. 3D rendering of the all axial slice views al-
lowed visualisation of the 3D model.
He-ion images of the MN arrays were generated using the Orion
Helium- ion microscope (Carl Zeiss Smt GmBH, Oberkochen, Ger-
many). He-ion technology relies on a novel high brightness helium
ion source of atomic dimensions. The helium beam was focused on
the sample with an ultimate probe size of 0.25 nm. The images
provide rich surface–speciﬁc information due to the unique nature
of the beam-sample interaction. The hollow MNs were imaged un-
der the following conditions: Acceleration 29.0 kV, dwell time
1.0 ls, blanker current 6.7 pA, working distance 22–23 mm.
2.4. Insertion force experiments of PC MN arrays
The force required to successfully insert the PC MNs into
excised porcine skin was determined using a TA.XT-plus Texture
Analyser (Stable Micro Systems, Surrey, UK). Neonate porcine skin
was obtained from stillborn piglets and immediately (<24 h after
birth) excised and trimmed to a thickness of approximately
400 lm using an electric dermatome (Integra Life Sciences™, Padg-
ett Instruments, NJ, USA). Skin was then stored in aluminium foil at
20 C until further use but for no longer than 2 weeks. Skin was
equilibrated in PBS for an hour and hair was removed using a dis-
posable razor. The SC surface of the skin was dried with tissue pa-
per and the skin was placed, dermis side down, on a 500 lm-thick
sheet of dental wax, and this assembly was then secured on a woo-
den block for support. MNs were attached to the tip of a moveable
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cyanoacrylate adhesive (Loctite, Dublin, Ireland). The test station,
in compression mode, then pressed MN arrays against the skin at
a speed of 0.5 mm/s for 30 s with known forces of 0.05, 0.10 and
0.40 N/needle. Following MN removal, methylene blue solution
(1% w/v) was applied onto the skin surface and left for 15 min. This
solution was then gently wiped off, ﬁrst with dry tissue paper and
then with saline and alcohol swabs. The surface of the stained skin
was then photographed using a digital camera (Nikon Coolpix
I120, Nikon UK Ltd., Surrey, UK) and the number of methylene
blue stained micro-conduits was simply counted.Fig. 1. Illustration of texture-analyzer set up for determination of fracture forces of
MN arrays.2.5. Optical coherence tomographic assessment of MN penetration into
neonatal porcine skin
The penetration characteristics of MNs following insertion into
excised full thickness (750 ± 20 lm) neonatal porcine skin was
determined using optical coherence tomography (OCT). The skin
was placed onto a section of dental wax for support. MNs were in-
serted using a custom-designed spring-activated applicator (Don-
nelly et al., 2010c), at a force of 11 N/per array, manually held in
place and immediately viewed using an EX1301 OCT Microscope
(Michelson Diagnostics Ltd., UK). The swept-source Fourier domain
OCT system has a laser centre wavelength of 1305.0 ± 15.0 nm,
facilitating real time high resolution imaging of the upper skin lay-
ers (7.5 lm lateral and 10.0 lm vertical resolution). The skin was
scanned at a frame rate of up to 15 B-scans (2D cross-sectional
scans) per second (scan width = 2.0 mm). Following MN removal,
the microporated skin was immediately viewed using OCT, as
above, to allow a determination of the depth and width of the pore
created within the skin. 2D images were analysed using the Na-
tional Institutes of Health imaging software ImageJ. The scale of
the image ﬁles obtained was 1.0 pixel = 4.2 lm, thus allowing
accurate measurements of the depth of MN penetration and the
width of pore created. The obtained 2D images were converted into
a 3D representation using the rendering programme Voxx2. To al-
low easy differentiation between MN and skin layers, false colours
were applied using Ability Photopaint Version 4.14.Fig. 2. Assembly of hollow MN arrays showing (A) the top view of MNs (B) the
lateral view of MNs (C) the three components of MNs, namely the MN array, the
modiﬁed barrel and the rubber headed plunger (D) the MN arrays glued to the
modiﬁed syringe.2.6. Fracture force experiments
In order to determine the axial forces (parallel to MN shaft)
necessary for mechanical fracture of the MN, MNs were again ﬁxed
to the tip of the moveable cylindrical probe of the Texture Analyser
using cyanoacrylate adhesive. An axial compression load was then
applied. The test station pressed the MN arrays against a ﬂat alu-
minium block at a rate 0.5 mm s1 with deﬁned forces for 30 s,
as shown in Fig. 1. Pre-test and post-test speed was 1 mm s1
and the trigger force was set at 0.049 N. MNs were subjected to de-
ﬁned forces of 0.05, 0.1, and 0.4 N/needle. All MNs of each array
were visually examined using a digital microscope before and after
fracture testing and changes in height were recorded by using the
digital microscope’s computer software.2.7. Production of hollow microneedle device
The hollow MN device was manufactured by cutting off the tip
of a 5 ml Terumo syringe. The diameter of the syringe was
16.0 mm. The MN array was cut into a circular (diameter
16.0 mm) to ﬁt directly onto the barrel of the syringe. It was sealed
using a silicone membrane and the three parts were ﬁxed together
using cyanoacrylate glue (Loctite, Dublin, Ireland). Syringe base to
MN array base measured 55.0 mm. The plunger of the syringe was
not modiﬁed and measured 70.0 mm in length (Fig. 2).2.8. Propagation of T4 phage to produce a high titre stock
An actively growing broth culture of the T4 phage host strain,
E. coli 11303, was prepared 18–24 h prior to propagation of T4
phage culture. Plates of 1.2% LB agar plus 0.5% NaCl were pre-
warmed in an incubator at 37 C. The 0.6% LB agar (soft agar for
overlay) (previously autoclaved) was liqueﬁed in a water bath,
then stored at 43–45 C until required. One aliquot (60 ll) of the
E. coli host strain was added to 2.5 ml of molten 0.6% LB agar.
The surface of the plates were overlaid with the soft agar and al-
lowed to set. Luria Bertani (LB) broth (1.0 ml) containing 0.5% NaCl
was added to the vial containing freeze-dried phage and 0.1 ml of
the rehydrated phage was spotted onto the overlay. The plate was
tilted to spread the rehydrated phage over as much of the surface
as possible. This was allowed to dry and incubated at 37 C
overnight.
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face of the agar plates using a sterile cell scraper. The soft agar
was centrifuged at 1000 rpm for 25 min to sediment the cellular
debris and agar. The supernatant was passed through a 0.22 lm
Millipore ﬁlter and the ﬁltrate was stored at 4–8 C.
2.9. Enumeration of phage titre using the double layer plaque assay
method
The double layer plaque assay method was adapted from a
method devised by Adams (1959). An actively growing broth cul-
ture of E. coli 11303 was prepared 18–24 h before performing the
plaque assay. Plates of 1.2% LB agar were pre-warmed in an incu-
bator at 37 C. Plates were prepared as previously described. Serial
dilutions of the samples obtained from the in vitro release study
were prepared from 101 to 108. The agar overlay was prepared
by adding 60 ll of the E. coli innoculum into 3 ml of 0.6% top agar
and poured immediately onto the 1.2% agar plates and agitated to
ensure even distribution. Samples of each serial dilution (20 ll)
were spotted onto the overlay, with 4–5 dilutions per plate. Each
sample was spotted in triplicate to ensure reproducibility. The
plates were incubated at 37 C overnight. Plaques were subse-
quently enumerated on plates at each dilution. Plaques appear as
deﬁned, circular zones of clearance within the bacterial lawn,
due to bacteriophage-mediated bacterial cell lysis. The concentra-
tion of bacteriophage present in each sample was calculated from
the dilution in which plaques were most countable, and using the
following equation:
Number of plaques dilution factor 50
¼ Concentration in PFU=ml ð1Þ
where 20 ll is plated, 50 to calculate PFU/ml. An average of the
three results was taken as the phage concentration.
2.10. In vitro release studies of bacteriophage T4 stock using hollow
MN device
The delivery of a stock solution (5  108 PFU/ml) of T4
bacteriophage across neonatal porcine skin, using the hollow MN
system was carried out using Franz diffusion cells (FDC-400 ﬂat
ﬂange, 15 mm oriﬁce diameter, mounted on an FDCD diffusion
drive console providing synchronous stirring at 600 rpm and
thermostated at 37 ± 1 C, Crown Glass Co. Inc., Sommerville, NJ,
USA). The oriﬁce diameter in the receptor compartment was
15 mm. No donor compartment was used, to allow ease of use of
the hollow MN device. The receptor compartment volume was cal-
culated to be 12 ml. PBS pH 7.4 (11 ml) was accurately dispensed
into the receptor compartment using a 5 ml Pipetteman,
assuming that the full 1000 ll would be delivered via the hollow
MN device. The PBS was degassed prior to use by sonication. Com-
partment temperatures were kept constant at 37 C by re-circulat-
ing water from a thermostatically controlled bath. The samples of
dermatomed (400 lm) and full thickness (750 ± 20 lm) neonatal
porcine skin were prepared by shaving carefully to remove hair
and was pre-equilibrated in PBS pH 7.4 (PBS) for 1 h before begin-
ning the experiments. A circular specimen of the skin was secured
to the receptor compartment of the diffusion cell using cyanoacry-
late glue (Loctite, Dublin, Ireland) with the SC side facing up. The
hollow MN device, with air expelled, was carefully inserted into
the ﬁxed dermatomed skin sample and approximately 1000 ll
was dispensed by exerting a constant pressure on the plunger of
the assembled MN device. This was done in triplicate for both
the dermatomed and full thickness skin. Using a long needle,
200 ll samples were removed from the side arm of the receptor
compartment at deﬁned time intervals and replaced with an equalvolume of pre-warmed degassed PBS. The samples were assayed
using the plaque assay method as described in Section 2.9.
2.11. In vivo delivery of bacteriophage T4 via the hollow microneedle
device
Four male Sprague–Dawley rats weighing 336 ± 14 g were used
in the experiment. To prevent hair from interfering with dermal
contact of the MN system, animals were anaesthetised using gas
anaesthesia (2–4% Isoﬂurane in oxygen). Before the experiment,
the hair was removed with an animal hair clipper. Additionally,
depilatory cream (Boots Expert, The Boots Company PLC, Notting-
ham, UK) was used to remove any residual hair. Skin barrier func-
tion was conﬁrmed as intact on a case by case basis by standard
transepidermal water loss measurements (Delﬁn Vapometer, Del-
ﬁn Technologies Ltd., Paris, France). A bacteriophage stock of con-
centration 4  109 PFU/ml was used in the experiment. A volume
of approximately 250 ll was administered at four different sites
on the back of each rat. Rats were anaesthetized prior to adminis-
tration of phages through the hollow MN system. The phage was
delivered by manually pushing the barrel of the device into the
rat skin until the hollow MN device was ﬁrmly in place and accu-
rately pipetting 250 ll into the barrel. The plunger was then care-
fully pressed downwards through the barrel and held for 30 s. After
phage administration, blood samples (100 ll) were collected at dif-
ferent time points over a 24 h period by lateral tail vein prick. Sam-
ples were taken at 0.5 h, 1 h, 1.5 h, 2 h, 4 h, 6 h and 24 h. All animal
experiments were conducted with ethical approval according to EC
Directive 86/609/EEC. The MN Research Group at Queen’s is com-
mitted to the three ‘‘R’’ principles of animal testing i.e. replace-
ment–substituting alternative non-animal systems in place of
live animal testing, reduction–using the fewest number of animals
possible and reﬁnement–developing procedures that limit the po-
tential for discomfort to animals.
2.12. Blood calibration curve
A calibration curve of known phage concentration within rat
blood versus detectable phage concentration was constructed. A
phage stock of 3  108 PFU/ml was used in the experiment. A
20 ll aliquot of this phage stock was added to 180 ll of rat blood
(i.e. a 1 in 10 dilution) and 20 ll of this dilution was added to an-
other 180 ll of rat blood. This serial dilution was continued to an
expected 3 PFU/ml concentration. Plaque assays were carried out
in triplicate and the average PFU/ml ± S.D. was plotted via the con-
centration calculated from phage stock. This curve was used to cor-
relate the actual phage stock concentration to concentrations
detected from blood samples. Linear regression analysis was used
to construct the equation of the line. The correlation coefﬁcient
(R2) was also calculated to assess the linearity of the data.
2.13. Statistical analysis
Where appropriate, statistical analyses of the results were per-
formed with a one-way analysis of variance, and a two-way anal-
ysis of variance (ANOVA). In all cases p < 0.05 was taken to
represent a statistically signiﬁcant difference. The software pack-
age used was GraphPad Prism 5 (GraphPad software Inc., San Die-
go, California, USA).3. Results
The images of the PC MN arrays are presented in Fig. 3. The
mean height and base diameter for the PC MNs were approxi-
mately 995 lm and 750 lm, respectively. The hollow bore diame-
Fig. 3. Images of PC hollowMN arrays using a variety of microscopy techniques. (a) Digital microscope images of single MN and a section of the MN array. (b) SEM images of a
single MN, the bore of the MN and a section of the MN array. (c) X-ray microtomography images of single MNs, the bore of the MN and the Mn array. (d) He-ion images of a
single MN, illustrating the bore of the needle and a radial view of the MN.
Fig. 4. (a) Inﬂuence of applied force on the reduction of PC MN height. Means ± S.D.
n = 7 MN on a single array (b) SEM image of following 0.4 N/needle axial force
application on PC MNs.
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images illustrate both the MN array and also the structure of the
reservoirs at the base of each MN. The He-ion technology produced
ultra sharp images of the PC needles. The rich surface speciﬁc
information is due to the unique nature of the beam- sample
interaction.
From the insertion forces studies of the PC arrays prior to fabri-
cation of the MN device, it was observed that, at all three forces
investigated (i.e. 0.05, 0.1 and 0.4 N/needle), MNs penetrated the
SC of the skin. Therefore, 100% penetration efﬁciency was observed,
regardless of the applied force.
Light microscope analysis showed that no decrease in MN
height was observed upon removal from skin, regardless of the
force of application.
Fracture force studies carried out on the MNs can be observed in
Fig. 4a. At forces of 0.05 N/needle, there was no signiﬁcant change
in MN height. However, when the axial force was increased, the%
reduction in height increased. Fig. 4b shows the morphology of
MNs following 0.4 N/needle force application, with apparent dam-
age at the tip of the needles. The 2D OCT image of the MNs follow-
ing insertion into neonatal porcine skin is illustrated in Fig. 5. It
was found that the MNs penetrated to an approximate depth of
700 lm and created a pore of approximate width 600 lm whilst
the MNs were in situ. Fig. 5 also shows a 3D image of MNs in situ
following insertion into neonatal porcine skin. It was found that,
immediately following the removal of MNs from the neonatal por-
cine skin, the residual skin pore had a depth of approximately
210 lm, and a width of approximately 600 lm but quickly closed
over (1 h, data not shown). 2D and 3D images of residual pores
in the neonatal porcine skin immediately following the removal
of the MNs are also shown. Release studies through dermatomed
skin showed that the hollow MN device had the ability to fully
penetrate the dermatomed skin (as was observed) and deliver bac-
teriophage transdermally. There was a small amount of liquid
remaining on the surface of the skin following application. Accord-
ingly, 100% delivery was not expected. A 1 ml volume of a
5  108 PFU/ml stock was delivered into 11 ml PBS in the Franz cell
donor compartment. Therefore, 4.5  107 PFU/ml would be the
maximum phage amount to be detected if 100% delivery occurred.Thirty minutes following delivery, 1  106 PFU/ml was detected
within the receptor compartment, as determined by plaque assay
(Fig. 6a). Amounts of phage detected stayed within 1  106 ±
1 log up to the 24 h time point. This is regarded as a constant level,
as variability of this kind is common with plaque assay results
(Darling et al., 1998).
Delivery of stock solution through full thickness skin proved
difﬁcult. MNs did not penetrate all layers of the skin and the resis-
tance provided by the dermal layer meant that solution ﬂow was
reduced, yielding a pool of liquid the skin surface (Fig. 6b).
Fig. 5. OCT images of PC MNs within skin. (a) A 2D OCT image of MNs in situ, following insertion into neonatal porcine skin at an application force of 11.0 N. (b) 2D image of
the pores created within neonatal porcine skin, following the insertion and removal of MNs. (c) A 3D representation of MNs in situ, following insertion into neonatal porcine
skin at an application force of 11.0 N. (d) 3D top view image of the pores created within neonatal porcine skin, following the insertion and removal of MNs.
Fig. 6. (a) Release study results of 1 ml phage stock delivered through dermatomed
and full thickness skin using the hollow MN device. Means ± S.D., n = 3. (b)
Photographic evidence of the ‘‘pool’’ created on top of full thickness skin following
delivery using the hollow MN device.
Fig. 7. (a) Calibration curve of phages in rat blood versus detectable phages via
plaque assay, illustrating the linearity of plaque assay results taken from the in vivo
study, with a comparable plaque assay of phage in rat blood. Means ± S.D., n = 3. (b)
In vivo release study results of T4 bacteriophage delivered by hollow PC MNs.
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phages were detectable in rat blood to a concentration of 30 PFU/
ml (Fig. 7a). Phage concentrations detected at each timepoint are
presented in Fig. 7b. Phage was detected at a concentration of
approximately 4  103 PFU/ml 30 min after phage administration.
This phage concentration reduced rapidly at the next time point
with an average 50 PFU/ml at 1.5 h and 125 PFU/ml at 2 h. Hypo-
thetically, 1 ml of a 4  109 PFU/ml stock was administered to each
rat (although it is known that 100% delivery did not occur due to
backﬂow of phage stock – Fig. 8). These results suggest that phages
were successfully delivered into the systemic circulation. However,
phages were also cleared quickly from the system, with an over
2 log reduction in phage concentration from 30 min to the 1 h timepoint. No phage was detected at the 24 h time point (Fig. 7b). The
variation in plaque assay results from the 1 h to the 6 h time points
can be explained by the known inherent variation of the microbi-
ological plaque assay itself, as outlined above.
Fig. 8. (a) Image of hollow MN device inserted through the skin of a rat, prior to
administration of phage stock. (b) Close up of microporations through the rat skin
created by hollow MNs (c) Image of microporations created by the hollow MN
device in one of the rats, following administration of phage stock. (d) Close up of
microporations through the rat skin created by hollow MNs, following phage stock
administration.
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A recent review by our Group illustrated the need for more di-
verse delivery systems to improve the breath of phage therapy
applications (Ryan et al., 2011).The present study successfully
delivered viable T4 bacteriophage transdermally both in vitro and
in vivo using a novel hollow MN system. MN–mediated transder-
mal delivery punctures the skin and by-passes the SC to create
transient aqueous transport pathways of micron dimensions. This,
in turn, enhances transdermal permeability (Tanner and Marks,
2008). MNs possess many advantageous attributes including pain-
less delivery, simple and affordable fabrication and the elimination
of the threat of cross-contamination that parenteral delivery poses
(Donnelly et al., 2010b, 2011; Garland et al., 2011). In dermatomed
skin, it was found that holes could be detected in porcine skin at
0.05 N/needle and 0.1 N/needle. This conﬁrmed that the SC barrier
would be penetrated at each of these insertion forces. As the SC
barrier is the principal barrier of the skin, once this barrier is brea-
ched, then transdermal transport is solely controlled by the prop-
erties of the drug delivery device employed, rather than the SC,
as the viable epidermis does not constitute a meaningful barrier
to drug penetration (Tanner and Marks, 2008).
Once it was conﬁrmed that rat blood did not interfere with the
plaque assay, a calibration plot was carried out to assess what con-centration of phages could be detected using the assay. With a
starting concentration of 3  108 PFU/ml, it was found that the
minimum limit of detection for the assay was 30 PFU/ml. The re-
duced concentration detected from the full thickness skin experi-
ment (approximately 3 log) compared to dermatomed skin was
due in part to the accumulation of phage stock on the surface of
the skin during phage delivery into full thickness skin. As MN could
not penetrate fully through full thickness skin, there was a high
amount of pressure which pushed the liquid to the surface of the
skin instead of through the skin. Therefore, it was expected that
the results for full thickness skin would be lower than for derma-
tomed skin. Examples of how clogging of the needle bore opening
during MN insertion and MN ﬂow resistance due to dense dermal
tissue compressed around the MN tip has previously been de-
scribed (Gardeniers et al., 2003; Martanto et al., 2006).
To combat the problem of phage stock loss on the surface of the
skin, a slightly altered administration procedure was adopted for
the in vivo study. Instead of a single administration at one site of
1 ml phage stock, four 250 ll aliquots were administered at four
different sites as it was hoped that a reduction in volume at each
site, would allow an increase in the volume of stock delivered
through the skin. The observed phage plasma proﬁle suggests that
this indeed was the case. Indeed, the in vivo study proved, for the
ﬁrst time, that live virus particles can be delivered transdermally
through a MN system. A previous study carried out by Inchley
(Inchley, 1969) reported that T4 bacteriophage administered to
mice by intravenous injection (5  108 PFU in 0.1 ml saline) were
rapidly cleared from the systemic circulation by the Reticuloendo-
thelial system (RES). It was found that the majority of phage (more
than 99%) was phagocytosed during the ﬁrst 30 min. Clearance
continued at this rate up to 1 h, after which a prolonged phase of
slower elimination occurred. By 6 h, approximately 104 PFU/ml
blood could be recovered and it had reduced to 2.7  102 PFU/ml
by 48 h. The study also concluded that 70–90% of recovered activ-
ity was located in the liver.
The present in vivo study detected 4.13  103 PFU/ml 30 min
following delivery. The absence of a suitable bacterial infection,
which would have allowed the phages to replicate, meant that
phages were cleared rapidly, as described above. It should also
be pointed out that, if the original concentration of phage stock
could be increased to 1012–1013 PFU/ml, a phage concentration of
approx 107 could possibly be achievable using the hollow MN
device. Some recent studies have examined the effect of phage con-
centration on the success of phage therapy. Barrow and co-workers
(Barrow et al., 1998) reported intramuscular administration of
bacteriophage R could control E. coli septicaemia in chickens and
meningitis in calves, and that a concentrations of phage as low
as 102 PFU intramuscularly provided some protection against
E. coli K1+ induced mortality (mortality 2/5 animals), however this
protection was not statistically signiﬁcant. In this study, higher
concentrations (104 and 106 PFU administered intramuscularly
provided signiﬁcant protection to both newly hatched and 3 week
old chickens (zero mortality). Generally, in vivo phage therapy
studies administered via the parenteral route require phage con-
centrations of 107–1010 PFU/ml for full eradication of bacterial
infections. This depends on the concentration of each bacterial spe-
cies within the body (Biswas et al., 2002; Cerveny et al., 2002;
Matsuzaki et al., 2003; Wills et al., 2005; McVay et al., 2007; Cap-
parelli et al., 2007). As has been explored by Payne et al. (2000) and
Payne and Jansen (2003), each phage-bacteria relationship is un-
ique, the concentrations of phage needed to eradicate speciﬁc con-
centrations of bacteria need to be characterised independently.
Capparelli et al. (2007) completed a study in which S. aureus sys-
temic infections were challenged intravenously with phage MSA.
A control group was set up in which 108 CFU/mouse of S. aureus
A170 was injected intravenously. Three other groups were intrave-
304 E. Ryan et al. / European Journal of Pharmaceutical Sciences 47 (2012) 297–304nously treated with phage MSA at ﬁnal concentrations of 107, 108
and 109 PFU/mouse respectively. All mice in the control group
and the lowest titre group (107) died within 4 days. The survival
rate 108 group was 40% and the mice treated with the highest con-
centration (109) all survived. This example shows how each phage-
bacteria relationship has a concentration threshold at which phage
therapy will be successful and therefore a general statement can-
not be made. If more phage was required, more MN-based ‘‘injec-
tions’’ could simply be made.
This hollow MN device successfully delivered a stock of T4
bacteriophage both in vitro and in vivo. Clearance occurred rapidly
in the in vivo rat models, as expected, due to the lack of an infection
model. It would be useful, in future studies, to carry out a similar
experiment using an E. coli rat infection model to demonstrate
the effectiveness of the MN-delivered phage in eradicating infec-
tions and to study the replication of phages and pharmacokinetics
of the phage-bacteria system.
This is the ﬁrst time that bacteriophages have been successfully
delivered transdermally. Bacteriophage delivery has the potential
to effectively improve the treatment of bacterial infections. It could
be a suitable alternative to antibiotic therapy in some cases and
may help overcome the present problem of antibiotic bacterial
resistance. Advantages of bacteriophages for treatment of bacterial
infections include their high speciﬁcity, self replication and good
safety proﬁles. Aside from antibacterial therapy, phages have a
plethora of other exciting applications. The possibility of delivering
phages via an easy to use MN device removes the risks associated
with parenteral delivery and would possibly allow for patient self-
administration. In order to achieve this, however, extensive further
studies are required in terms of delivery device optimisation and,
ultimately, human clinical trials.
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